Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.
Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation[1].Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity[1].
Acasunlimab (GEN1046; 5 mg/kg; twice weekly for three cycles) has antitumor activity and inhibits tumor growth in double knock-in (dKI) transgenic C57BL/6 mice[1].
References:
[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.
[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178.